Teva Pharmaceutical Industries Ltd. announced the launch of a generic version of Uceris1 (budesonide) extended-release tablets, 9 mg, in the U.S.
Budesonide extended-release tablets are a glucocorticosteroid indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis.
“The launch of generic budesonide extended-release tablets signals an important addition to Teva’s portfolio,” said Brendan O’Grady, EVP and head of North America Commercial. “We continue to be focused on bringing affordable generic treatment options to our customers, including those living with chronic, life-long conditions like ulcerative colitis.”
With nearly 550 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market and holds the leading position in first-to-file opportunities, with over 100 pending first-to-files in the U.S. Currently, one in seven generic prescriptions dispensed in the U.S. is filled with a Teva generic product.
Uceris had annual sales of approximately $196 million in the U.S., according to IMS data as of May 2018.
_______________________________________________________________
Reference:
1 Uceris® is a registered trademark of Santarus, Inc. and Valeant Pharmaceuticals International
(Source: Teva Pharmaceutical Industries Ltd.)
